Pyoderma gangrenosum
Pyoderma gangrenosum is in seldsume, inflammatoare hûdsykte wêrby't pynlike pustules of knobbels ulcers wurde dy't stadichoan groeie. Pyoderma gangrenosum is net besmetlik. Behannelingen kinne omfetsje corticosteroids, ciclosporine, of ferskate monoklonale antykladen. Hoewol it minsken fan elke leeftyd kin beynfloedzje, hat it meast ynfloed op minsken yn har 40's en 50's.
☆ Yn 'e 2022 Stiftung Warentest-resultaten út Dútslân wie de konsuminttefredenheid mei ModelDerm mar wat leger dan mei betelle telemedisynkonsultaasjes.
Op 'e skonk fan in persoan mei ulcerative kolitis.
References
Pyoderma gangrenosum is in seldsume hûdbetingsten dy't pynlike zweren feroarsaket mei reade of pearse rânen. It is klassifisearre as in inflammatoire sykte en is diel fan in groep neamd neutrofiele dermatoses. De oarsaak fan pyoderma gangrenosum is kompleks, mei problemen mei sawol oanberne as adaptive immuniteit yn minsken dy't genetysk gefoelich binne. Koartlyn hawwe ûndersikers har rjochte op 'e hierfollikel as in mooglik útgongspunt fan' e sykte.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum is in seldsume hûdkondysje dy't ekstreem pynlike zweren feroarsaket. Wylst wy de oarsaak net folslein begripe, witte wy dat it om ferhege aktiviteit fan bepaalde ymmúnsellen giet. De behanneling fan de sykte is noch net maklik. Wy hawwe ferskate medisinen dy't it ymmúnsysteem ûnderdrukke of har aktiviteit feroarje. Njonken dizze rjochtsje wy ús ek op it behanneljen fan de wûnen en it behearen fan pine. Corticosteroids en cyclosporine binne faak de earste kar foar behanneling, mar de lêste tiid is d'r mear ûndersyk west oer it brûken fan biologyske terapyen lykas TNF-α-ynhibitoren. Dizze biologyske medisinen wurde hieltyd mear de foarkar, foaral yn pasjinten mei oare inflammatoire omstannichheden, en se wurde earder brûkt yn it sykteproses.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
